Physician profile
Steven A Gorcey
NPI 1679512941
$6,467.09
in general payments reported to CMS, 2019-2025
27 companies · $1,720 in 2025
The $1,720 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $198 · 2021: $974 · 2022: $877 · 2023: $1,004 · 2024: $1,367 · 2025: $1,720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,055 · Education: $36.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,054.88 |
| Education | $36.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,342.23 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $929.73 | 2019-2025 | Xifaxan, Relistor, Plenvu |
| Janssen Biotech, INC. | $870.93 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Madrigal Pharmaceuticals | $623.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $511.91 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $482.34 | 2024-2025 | Voquezna |
| Celgene Corporation | $470.41 | 2021-2024 | Zeposia |
| Genzyme Corporation | $275.57 | 2022-2025 | |
| Gilead Sciences, INC. | $191.58 | 2019-2023 | |
| Qol Medical, LLC | $162.46 | 2021-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $99.97 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $75.38 | 2023-2024 | Ibsrela |
| Ferring Pharmaceuticals INC. | $60.06 | 2022-2023 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $57.35 | 2019-2024 | Entyvio |
| Romark Laboratories, Lc | $45.74 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $45.70 | 2023-2025 | Dupixent |
| Organon LLC | $41.58 | 2022-2023 | Renflexis |
| Lucid Diagnostics INC. | $31.88 | 2021 | |
| Braintree Laboratories, INC. | $25.11 | 2020-2022 | |
| Medtronic, INC. | $16.78 | 2021 | |
| Endogastric Solutions, INC | $16.58 | 2024 | Esophyx |
| Echosens North America, INC. | $16.10 | 2023 | Fibroscan |
| Daiichi Sankyo INC. | $15.93 | 2020 | |
| Ironwood Pharmaceuticals, INC | $15.56 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.59 | 2023 | Cyltezo |
| Ipsen Biopharmaceuticals, INC | $14.03 | 2025 | Iqirvo |
| Celltrion USA INC. | $13.78 | 2024 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Gorcey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.